M
Mark Lunt
Researcher at University of Manchester
Publications - 430
Citations - 23187
Mark Lunt is an academic researcher from University of Manchester. The author has contributed to research in topics: Population & Rheumatoid arthritis. The author has an hindex of 77, co-authored 391 publications receiving 20723 citations. Previous affiliations of Mark Lunt include Norfolk and Norwich University Hospital & Central Manchester University Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
TL;DR: In patients with active RA, anti-TNF therapy was not associated with increased risk of overall serious infection compared with DMARD treatment, after adjustment for baseline risk, but the rate of serious skin and soft tissue infections was increased, suggesting an important physiologic role of TNF in host defense in the skin andsoft tissues beyond that in other tissues.
Journal ArticleDOI
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century
Deborah P M Symmons,G. Turner,Roger T. Webb,P. Asten,E M Barrett,Mark Lunt,David Scott,Alan J. Silman +7 more
TL;DR: The prevalence of RA in women, but not in men, in the UK may have fallen since the 1950s, and the age- and sex-specific point prevalence figures are therefore an underestimate.
Journal ArticleDOI
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
William G Dixon,Kimme L. Hyrich,Kath D. Watson,Mark Lunt,James Galloway,Andrew Ustianowski,Deborah P M Symmons +6 more
TL;DR: The rate of TB in patients with RA treated with anti-TNF therapy was three- to fourfold higher in patients receiving INF and ADA than in those receiving ETA.
Journal ArticleDOI
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS).
Dieter Felsenberg,Alan J. Silman,Mark Lunt,G Armbrecht,A A Ismail,J. D. Finn,W Cockerill,D. Banzer,L. I. Benevolenskaya,Ashok K. Bhalla,Bruges Armas J,J.B. Cannata,Cyrus Cooper,J. Dequeker,R. Eastell,B. Felsch,W. Gowin,S. Havelka,K. Hoszowski,I. Jajic,J. Janott,Olof Johnell,J. A. Kanis,G. Kragl,Lopes Vaz A,Roman S. Lorenc,George P. Lyritis,P. Masaryk,Christine Matthis,Tomasz Miazgowski,G. Parisi,H. A. P. Pols,Gyula Poór,Heiner Raspe,David M. Reid,W. Reisinger,Schedit-Nave C,Jan J. Stepan,Chris Todd,K. Weber,Anthony D. Woolf,O.B. Yershova,J. Reeve,Terence W O'Neill +43 more
TL;DR: The data confirm the frequent occurrence of the disorder in men as well as in women and the rise in incidence with age and some evidence of geographic variation in fracture occurrence; rates were higher in Sweden than elsewhere in Europe.
Journal ArticleDOI
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
TL;DR: The hypothesis that the powerful antiinflammatory effect of anti–tumor necrosis α (anti-TNFα) therapy might lead to a reduction in the incidence of myocardial infarction (MI) in patients with RA is tested, and it is indicated that RA patients treated with anti-T NFα do not have a lower incidence of MI compared with RA patients treating with traditional DMARDs.